Wyss Center and BrainScape Medical Team Up for Epios® Launch
Wyss Center Collaborates with BrainScape Medical
The Wyss Center for Bio and Neuro Engineering has announced a significant partnership with BrainScape Medical, a pioneer company focusing on long-term brain monitoring and neurostimulation. This collaboration is a major leap towards transforming innovative neurotechnology into widely available clinical remedies.
Understanding Epios® Technology
As part of this collaboration, the Wyss Center has provided BrainScape Medical with an exclusive license for Epios®, a state-of-the-art platform that enables continuous brain activity monitoring. With its minimally invasive design, Epios® aims to better diagnose and treat neurological ailments. The results from first-in-human trials highlight its potential in clinical applications.
Benefits of Epios® in Neurological Care
Epios® utilizes full-head subscalp EEG monitoring, employing minimally invasive electrodes for ongoing brain activity observation. This capability is essential for efficiently managing neurological conditions such as epilepsy and dementia. The system's unique integration of monitoring with neuromodulation permits real-time therapeutic responses. Dr. Erwin Böttinger, Director of the Wyss Center, expressed excitement over the significant advancement of Epios® towards practical clinical use. He stated that this partnership signifies a commitment to developing impactful neurotechnologies that can directly benefit patients in their daily lives.
Quotes from Leadership
Laura Johnson, CEO of BrainScape Medical, remarked that Epios® symbolizes a major breakthrough in neurotechnology. She emphasized the company’s mission to provide this innovative solution globally, enhancing the management and treatment journey of patients with neurological disorders. This dual focus on better diagnosis and patient experience underlines the essence of their collaborative efforts.
About the Wyss Center
The Wyss Center serves as an independent, not-for-profit establishment aimed at pioneering neurotechnologies designed to improve the well-being of individuals with neurological and mental health challenges. Located at Campus Biotech in Geneva, Switzerland, the Center is dedicated to developing groundbreaking solutions through artificial intelligence, bioengineering, and neuroengineering. With the vision to restore vital neural functions and provide accurate therapies, the Center was founded in 2014 thanks to the support of Swiss entrepreneur Hansjörg Wyss. Their collaborative projects strive to foster innovation while maximizing the impact on clinical practices beyond borders.
Innovation in Neurological Treatments
This partnership not only underscores the dedication to progress in neurotechnology but also opens new avenues for better patient outcomes and experiences. Discovering and advancing technologies like Epios® will likely shift how brain disorders are diagnosed and treated, heralding a new era in patient care.
Frequently Asked Questions
What is the main purpose of the Wyss Center and BrainScape Medical partnership?
The primary goal of their partnership is to advance the Epios® technology for improved brain monitoring and treatment of neurological disorders.
What type of technology does Epios® use?
Epios® employs full-head subscalp EEG monitoring with minimally invasive electrodes for continuous brain activity tracking.
Who are the key leaders involved in this initiative?
Dr. Erwin Böttinger, Director of the Wyss Center, and Laura Johnson, the CEO of BrainScape Medical, are notable leaders advocating for this project.
What conditions can Epios® help manage?
Epios® is designed to aid in managing neurological conditions such as epilepsy and dementia, providing real-time monitoring and therapeutic approaches.
When was the Wyss Center established?
The Wyss Center was established in 2014, built on the vision and support of philanthropist Hansjörg Wyss, targeting advancements in neurotechnology.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
